Upstream Bio, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 5 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Upstream Bio has 4 disclosed suppliers and 1 disclosed customer in SEC filings.
Upstream Bio, Inc.
3.40
SentenceBy assuming and accepting Astellas' surviving obligations under the Terminated Regeneron License Agreement, we are required to pay Regeneron mid-single-digit percentage royalties on aggregate worldwide net sales of any product developed by or on behalf of us that contains the Compound as an ingredient or component of the materials sold (a "Royalty Product") during the royalty term.
SentencePursuant to the Astellas Asset Purchase Agreement, we purchased from Astellas the compound designated by Astellas as ASP7266 (the "Compound," which was subsequently renamed by us as verekitug).
UPB 10-Kaccession 0001193125-26-126188
SentenceDuring each of the years ended December 31, 2025 and 2024, we made an annual payment to Lonza in the amount of $0.5 million pursuant to the Lonza License Agreement.
UPB 10-Kaccession 0001193125-26-126188
SentenceIn accordance with the Lonza License Agreement, we entered into a sublicense with Wuxi Biologics (Hong Kong) Limited to manufacture the Compound, requiring us to pay a mid-six-figure annual fee to Lonza pursuant to this provision.
UPB 10-Kaccession 0001193125-26-126188
SentenceDuring the years ended December 31, 2025 and 2024, we received payments from Maruho in the amount of $2.8 million and $1.9 million, respectively.
UPB 10-Kaccession 0001193125-26-126188
Linked news
NewsExpected move
No implied move.